Featured Press Releases

FDA Accepts sBLA Filing of Leqembi® (lecanemab-irmb) for IV Maintenance Dosing in Early Alzheimer

FDA Accepts sBLA Filing of Leqembi® (lecanemab-irmb) for IV Maintenance Dosing in Early Alzheimer's Treatment

Samsung Bioepis and Organon’s HADLIMA™ Gains FDA Interchangeability Designation, Expanding Access to Adalimumab Alternative

Samsung Bioepis and Organon’s HADLIMA™ Gains FDA Interchangeability Designation, Expanding Access to Adalimumab Alternative

  • 27 May 2025

Samsung Bioepis Co., Ltd. and Organon & Co. announced that the US Food and Drug Administration...

GenScript

GenScript's ProBio subsidiary plays a key role in cutting-edge cancer therapies

Gilead’s Livdelzi® Shows Sustained Efficacy in PBC, Reducing ALP, Relieving Itch, and Potentially Slowing Disease Progression

Gilead’s Livdelzi® Shows Sustained Efficacy in PBC, Reducing ALP, Relieving Itch, and Potentially Slowing Disease Progression

Strategic Expansion Expands Fusion Orthopedics

Strategic Expansion Expands Fusion Orthopedics' Foot & Ankle Reach

Dr. Alastair Leighton, a biopharma veteran, has been hired as Chief Operating Officer by Chemify

Dr. Alastair Leighton, a biopharma veteran, has been hired as Chief Operating Officer by Chemify

Bayer’s AMBELVIST® (gadoquatrane) Gains FDA Approval for Contrast-Enhanced MRI in Detection of Lesions with Abnormal Vascularity Across CNS and Non-CNS Body Regions

Bayer’s AMBELVIST® (gadoquatrane) Gains FDA Approval for Contrast-Enhanced MRI in Detection of Lesions with Abnormal Vascularity Across CNS and Non-CNS Body Regions

  • Bayer
  • 15 Jun 2026
EVERY and Huvepharma Announce Fourfold Expansion of Production Capacity

EVERY and Huvepharma Announce Fourfold Expansion of Production Capacity

  • The EVERY Company
  • 15 Jun 2026
Results from Incyte’s Phase 3 frontMIND Trial of Tafasitamab Combination Show Prolonged Progression-Free Survival Presented at EHA 2026

Results from Incyte’s Phase 3 frontMIND Trial of Tafasitamab Combination Show Prolonged Progression-Free Survival Presented at EHA 2026

  • Incyte
  • 15 Jun 2026
AbbVie Presents EHA 2026 Data on VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Nine-Year Outcomes

AbbVie Presents EHA 2026 Data on VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Nine-Year Outcomes

  • AbbVie
  • 12 Jun 2026
Leading Dermatologist Dr. Dendy Engelman Joins ELASTEN® to Advance the Future of Science-Backed Skin Health from Within

Leading Dermatologist Dr. Dendy Engelman Joins ELASTEN® to Advance the Future of Science-Backed Skin Health from Within

  • QUIRIS Healthcare
  • 11 Jun 2026
Breast Milk–Inspired Synbiotic for Infant Gut Health Developed Through Partnership Between NurtureBio and Lallemand

Breast Milk–Inspired Synbiotic for Infant Gut Health Developed Through Partnership Between NurtureBio and Lallemand

  • NurtureBio
  • 11 Jun 2026
The Digital Pharma Advances Conference 2026

Most Popular
June   2026
M T W T F S S
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30          

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.